TRUSOPT Preservative-Free 20 mg/ml eye drops, solution in single-dose container Ireland - English - HPRA (Health Products Regulatory Authority)

trusopt preservative-free 20 mg/ml eye drops, solution in single-dose container

santen oy - dorzolamide - eye drops, solution in single-dose container - 20 milligram(s)/millilitre - carbonic anhydrase inhibitors; dorzolamide - antiglaucoma preparations and miotics, carbonic anhydrase inhibitors, dorzolamide - it l is indicated: as adjunctive therapy to beta-blockers; as monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are contraindicated; in the treatment of elevated intra-ocular pressure in: ocular hypertension; open-angle glaucoma; pseudoexfoliative glaucoma.

COSOPT 20 mg/ml + 5 mg/ml eye drops, solution United Kingdom - English - myHealthbox

cosopt 20 mg/ml + 5 mg/ml eye drops, solution

santen oy - dorzolamide hydrochloride - eye drops, solution. - 22.26 mg - antiglaucoma preparations and miotics, beta blocking agents, timolol, combinations - indicated in the treatment of elevated intraocular pressure (iop) in patients with open-angle glaucoma or pseudoexfoliative glaucoma when topical beta-blocker monotherapy is not sufficient.

 COSOPT Preservative-Free 20 mg/ml + 5 mg/ml eye drops, solution United Kingdom - English - myHealthbox

cosopt preservative-free 20 mg/ml + 5 mg/ml eye drops, solution

santen oy - dorzolamide hydrochloride - eye drops, solution, single dose container - 22.26 mg - antiglaucoma preparations and miotics, beta blocking agents, timolol, combinations - indicated in the treatment of elevated intraocular pressure (iop) in patients with open-angle glaucoma or pseudoexfoliative glaucoma when topical beta-blocker monotherapy is not sufficient.

COSOPT 20mg/ml + 5mg/ml eye drops, solution Ireland - English - HPRA (Health Products Regulatory Authority)

cosopt 20mg/ml + 5mg/ml eye drops, solution

santen oy - dorzolamide; timolol - eye drops, solution - 20+5 milligram(s)/millilitre - beta blocking agents1); timolol, combinations

OVAGEN New Zealand - English - Ministry for Primary Industries

ovagen

mai new zealand ? icpbio reproduction ltd - follicle stimulating hormone-pituitary - follicle stimulating hormone-pituitary 1,000 g/kg - endocrine agent (hormone)

IMOVAX RABIES POWDER FOR SUSPENSION Canada - English - Health Canada

imovax rabies powder for suspension

sanofi pasteur limited - rabies vaccine inactivated (human diploid-cell culture) - powder for suspension - 2.5unit - rabies vaccine inactivated (human diploid-cell culture) 2.5unit - vaccines

MACUGEN SOLUTION Canada - English - Health Canada

macugen solution

pfizer canada ulc - pegaptanib - solution - 0.3mg - pegaptanib 0.3mg - eent drugs, miscellaneous

IMOGAM RABIES-HT- human rabies virus immune globulin injection, solution United States - English - NLM (National Library of Medicine)

imogam rabies-ht- human rabies virus immune globulin injection, solution

sanofi pasteur inc. - human rabies virus immune globulin (unii: 95f619atq2) (human rabies virus immune globulin - unii:95f619atq2) - human rabies virus immune globulin 150 [iu] in 1 ml - rabies immune globulin (human) heat treated, imogam rabies – ht, in conjunction with the standard series of rabies vaccine vaccinations, is indicated for individuals suspected of exposure to rabies, particularly severe exposure, with one exception: persons who have been previously immunized with rabies vaccine. previously immunized persons are those who have had a documented rabies virus neutralizing antibody titer and who have completed one of the recommended regimens (pre-exposure or post-exposure) with a cell culture vaccine or another vaccine. administer only vaccine to these persons (i.e., post-exposure for a person previously vaccinated). (1) inject imogam rabies – ht, as promptly as possible after exposure, along with the first dose of vaccine. if initiation of treatment is delayed for any reason, still administer imogam rabies – ht and the first dose of vaccine, regardless of the interval between exposure and treatment. if rabies immune globulin (human) was not administered when vaccination was begun

IMOVAX RABIES (rabies virus strain pm-1503-3m antigen- propiolactone inactivated and water kit United States - English - NLM (National Library of Medicine)

imovax rabies (rabies virus strain pm-1503-3m antigen- propiolactone inactivated and water kit

sanofi pasteur inc. - rabies virus strain pm-1503-3m antigen (propiolactone inactivated) (unii: c4hqf74xmw) (rabies virus strain pm-1503-3m antigen (propiolactone inactivated) - unii:c4hqf74xmw) - rabies virus strain pm-1503-3m antigen (propiolactone inactivated) 2.5 [iu] in 1 ml - imovax rabies is a vaccine indicated for pre-exposure and post-exposure prophylaxis against rabies. imovax rabies vaccine is approved for use in all age groups. physicians must evaluate each possible rabies exposure. local or state public health officials should be consulted if questions arise about the need for prophylaxis. (11) the following factors should be considered before antirabies prophylaxis is initiated. rabid bats have been documented in the 49 continental states, and bats are increasingly implicated as important wildlife reservoirs for variants of rabies virus transmitted to humans. transmission of rabies virus can occur from minor, seemingly underappreciated or unrecognized bites from bats (see table 2). (11) raccoons, skunks, and foxes are the terrestrial carnivores most often infected with rabies in the united states. suggestive clinical signs of rabies among wildlife cannot be interpreted reliably. all bites by such wildlife should be considered possible exposures to rabies virus. post-exposu